Cabaletta Bio, Inc.

NASDAQ:CABA

Biotechnology

Healthcare
$1.06 +1.23%

+$0.04 today

Market cap
$227.58M
Beta
3.23
P/E (TTM)
-1.8
EPS (TTM)
-$1.57
52W Low $1.26High $4.23

Volume 4.13M

Average 3.33M

CABA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Cabaletta Bio, Inc.NASDAQ: CABA

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 112.03M shares rose 126.2% year over year, ahead of the +91.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 9.5% from the prior quarter. Over 3 fiscal years it compounded at +51.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +126.2% holds above the trailing-twelve-month pace of +91.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
112.03M+9.5% QoQ
Last fiscal yearDec 2025
102.26M+106.5% YoY
LTMMar 2026
94.61M+91.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+126.2%——
1 year+106.5%——
3-year CAGR+51.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
102.26M USD
Year-over-year change
+106.5%
4-year CAGR
+41.2%

Weighted Avg Shares vs competitors

How CABA compares with its peers on the latest reported figures

  • CABA's LTM Mar 2026 weighted avg shares of 94.61M shares is the 5th highest of the 11 companies compared; the peer median is 85.16M shares.
  • Its year-over-year change of +91.6% is the 2nd highest of 11, against a peer median of +20.5%.
  • Over three fiscal years its annual growth of +51.6% compares with a peer median of +15.4%.
CABA Competitors Peer median
Weighted Avg Shares for CABA and competitors
Company Period LTM YoY 3-year CAGR
ALLOAllogene Therapeutics, Inc.LTM Mar 2026225.47M +9.3%+15.5%
HUMAHumacyte, Inc.LTM Mar 2026167.44M +37.1%+15.3%
IMMPImmutep LimitedFY2025145.58M +21.3%+19.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026104.77M +19.6%+13.7%
CABACabaletta Bio, Inc.LTM Mar 202694.61M +91.6%+51.6%
EDITEditas Medicine, Inc.LTM Mar 202690.28M +9.3%+8.9%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 202680.03M -5.4%-0.7%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 202665.52M +98.2%+28.7%
CAPRCapricor Therapeutics, Inc.LTM Mar 202649.43M +35.6%+23.7%
KYTXKyverna Therapeutics, Inc.LTM Mar 202648.56M +12.5%+19.7%
LYELLyell Immunopharma, Inc.LTM Mar 202618.01M +34.2%+11.4%
Peer median (excluding CABA) 85.16M+20.5%+15.4%

Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development32.49M39.3M55.42M97.2M142.67M
Selling, General & Admin13.82M14.84M19.24M27.94M29.57M
Operating Expenses46.31M54.14M74.66M125.14M172.24M
Depreciation & Amortization733K1.18M1.43M1.71M1.65M
EBITDA(45.56M)(51.8M)(66.25M)(113.41M)(164.21M)
EBITDA Margin—————
Operating Income(46.31M)(54.14M)(74.66M)(125.14M)(172.24M)
Operating Margin—————
Interest Income24K1.16M6.99M10.03M6.03M
Interest Expense000748K2M
Other Income / Expenses24K1.16M6.99M9.28M4.39M
Income Before Tax(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Net Margin—————
EPS (Basic)(1.80)(1.81)(1.65)(2.34)(1.64)
EPS (Diluted)(1.80)(1.81)(1.65)(2.34)(1.64)
Weighted Avg Shares25.74M29.34M40.95M49.52M102.26M
Weighted Avg Shares (Diluted)25.74M29.34M40.95M49.47M102.26M

Cabaletta Bio, Inc.

NASDAQ:CABA

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.